

PERSONAL INFORMATION

Alexandros Pintzas

 Institute of Chemical Biology
<https://www.eie.gr/en/institutes/icb/>
<https://www.eie.gr/en/institutes/icb/research/research-disciplines/molecular-and-cellular-biology-for-basic-and-translational-research/signal-mediated-gene-expression/>
National Hellenic Research Foundation
Athens, Greece

 +30-210 7274753  30 6972007920

 apint@eie.gr

WORK EXPERIENCE

2002-2025: Research Director, Head of Signal Mediated Gene Expression Laboratory, ICB, NHRF, Athens. 2026-: Researcher, Principal Investigator, ICB/NHRF

2020-2024: Director, Institute of Chemical Biology (ICB), National Hellenic Research Foundation (NHRF), Athens

2020-2024 : Vice President of NHRF's Board of Directors

2012-2019: Director, Institute of Biology, Medicinal Chemistry and Biotechnology IBMCB/NHRF, Athens

2011- 2012: Director, Institute of Biological Research and Biotechnology (IBRB), NHRF, Athens

1996- 2002: Research Associate Professor, Lab Head, IBRB, NHRF, Athens

1993-1996: Res. Assistant Prof., Inst. Biol. Res. Biotech., NHRF

1992–1995: Senior Fellow, Institute of Biological Chemistry, LGME-CNRS, (currently IGBMC), School of Medicine, University of Strasbourg, France.

1989-1992: Post-doctoral Research Fellow, CRC (currently CRUK) Beatson Institute for Cancer Research, Glasgow, U.K.

1985-1989: Functional Scientist, Dept. of Virology, Hellenic Pasteur Institute, Athens, Greece.

EDUCATION AND TRAINING

-1989-1992: Post-doctoral Research Fellow, CRC (currently CRUK) Beatson Institute for Cancer Research, Glasgow, U.K.

-1985-1989: **PhD in Biochemistry- Molecular Biology**, Dept. of Biology, University of Athens

-1976-1981: **BSc in Chemistry**, Dept. of Chemistry, University of Athens

HONORS/AWARDS/DISTINCTIONS

-1990-1991: Long-term EMBO (European Molecular Biology Organisation) Post-doctoral fellowship

-1992-1993: Post-doctoral fellowship by the French Organisation against Cancer (ARC)

-1993-1994: EU Marie Curie Post-doctoral fellowship (HCM)

-1996: Fellowship from the Royal Society of U.K.

PUBLICATIONS

Brief sentence of description of my work: My research interests have been in the scientific areas of Biology of Cancer and Cell Death, towards exploitation of the interplay of proliferative with apoptotic/ autophagic pathways for novel cancer therapeutics and their rational combinations.

Bibliometric data

Publications: 71. Peer-reviewed articles in international refereed journals: 67. Submitted: 1
 Papers in book chapters: 4. Total I.F.: 330.0, average I.F.: 5.2
 Senior author (incl. corresponding author) peer-reviewed: 42
 Total citations: 3131 (Scopus, WoS), 4420 (Google Scholar)
 Senior author citations: 2551 (Scopus, WoS)
 h index: 31 (Scopus, WoS), 36 (Google Scholar)
 Papers in refereed proceedings of International Conferences and book chapters: 3

SELECTED RELATED PUBLICATIONS

Batsi, Y., Antonopoulou, G., Galatis-Vaxovanos, C., Goulielmaki, M., Koumaki, K., Papalouka, C., Poulou-Sidiropoulou, E., Kosmidou, V., Vidali, M.-S., Kritsi, E., Potamitis, C., Douna, S., Gkotsi, E.-F., Magoulas, G.E., Chatziioannou, A., Souliotis, V.L., Pletsas, V., Papadodima, O., Zoumpourlis, V., Zervou, M., Georgiadis, P., **Pintzas, A.**, Kostas, I.D. (2026). 2-Cyclopropanecarboxamido, 6-Carboxamide Substituted Benzothiazoles: Design, Synthesis, in vitro and in vivo Evaluation of their Antiproliferative and Anti-tumorigenic Activity. *Bioorganic & Medicinal Chemistry* 132:118450. doi: 10.1016/j.bmc.2025.118450.

Paolo G. Casali, Hélène Antoine-Poirel, Jean-Yves Blay, Thomas Dubois, Andrea Ferrari, Ane Fullaondo, Eivind Hovig, Iwona Lugowska, Stein Kaasa, Delia Nicoară, Vasiliki Pletsas, Salvatore Provenzano, Piotr Rutkowski, Muriel Santoro, Mario Šekerija, Wannas Van Hoof, Malvika Vyas, Annalisa Trama, **on behalf of the JANE Consortium*** (2025). Health networking on cancer in the European Union: a “green paper” by the EU Joint Action on Networks of Expertise (JANE). *ESMO Open*. 2025 Feb;10(2):104126. doi: 10.1016/j.esmoop.2024.104126.

Koumaki K., Skarmalioraki, S., Kosmidou, V., Krikoni, L., Goulielmaki, M., Zoumpourlis, V., **Pintzas A.**,* Souliotis, V.L. (2025). Antitumorigenic effect of combination treatment with BRAFi and cisplatin in colorectal cancer in vitro and in vivo. *Advanced Therapeutics* Volume 8, Issue 1 January 2025 Article number 2400250

Vlachavas E-I., Voutetakis, K., Kosmidou, V., Tsikalakis, Roditis, S., Pateas, K., Kim, R., Pagel, K., Wolf, S., Warsow, G., Dimitrakopoulou-Strauss, A., Zografos, G.N., **Pintzas, A.**, Betge, J., Papadodima, O. and Wiemann, S. (2025). Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer. *Mol.Oncology*. 2025 Jun;19(6):1751-1774. doi: 10.1002/1878-0261.13814.

Batsi, Y., Antonopoulou, G., Fotopoulou, T., Koumaki, K., Kritsi, E., Potamitis, K., Goulielmaki, M., Skarmalioraki, S., Papalouka, C., Poulou-Sidiropoulou, E., Kosmidou, V., Douna, S., Vidali, M.-S., Gkotsi, E.-F., Chatziioannou, A., Souliotis, V.L., Pletsas, V., Papadodima, O., Zoumpourlis, V., Georgiadis, P., Zervou, M., **Pintzas, A.**, and Kostas I.D. (2023). Design and Synthesis of Novel 2-Acetamido, 6-Carboxamide Substituted Benzothiazole Derivatives as Potential BRAFV600E Inhibitors – *In vitro* Evaluation of their Antiproliferative Activity. *ChemMedChem* 2023, 18 (22), e202300322 (Open Access) <https://doi.org/10.1002/cmdc.202300322>.

Koumaki K., Kontogianni, G., Kosmidou, V., Pachitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O. and **Pintzas, A.*** (2021). BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600E CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. *BBA Molecular Basis of Disease* 1867, 166061

Kosmidou, V., Vlassi, M., Anagiotos, K., Raftopoulou, S., Kalogerakou, E., Aggeli, C., Choreftaki, T., Zografos, G., **Pintzas, A.*** (2021). Noxa upregulation and a 5-gene (Noxa, Mcl1, cIAP1, cIAP2, DR5) mRNA expression profile may provide an apoptotic biomarker panel with very significant differential diagnostic potential in colorectal cancer. *European Journal of Clinical Investigation* 51: e13353

Giopanou, I*, **Pintzas, A.*** (2020). RAS and BRAF in the foreground for Non-Small Cell Lung Cancer and Colorectal Cancer: similarities and main differences for prognosis and therapies. *Critical Reviews in Oncology / Hematology*, 146, 102859

Vlachavas, E., Pilalis, E., Papadodima, O., Koczan, D., Willis, S., Klippel, S., Cheng, C., Pan, L., Sachpekidis, C., **Pintzas, A.**, Gregoriou, V., Dimitrakopoulou-Strauss, A., and Chatziioannou, A. (2019). Radiogenomic analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and gene expression data elucidates the epidemiological complexity of colorectal cancer landscape. *Computational and Structural Biotechnology Journal*.17:177-185

Devetzi, M., Kosmidou, V., Vlassi, M., Perysinakis, I., Aggeli, C., Zografos G.N., and **Pintzas A.*** (2016). Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. *Sci. Rep.* 6:36532.

Goulielmaki, M., Koustas, E. Moissidou, E., Vlassi, M., Sasazuki, T., Shirasawa, S., Zografos, G., Oikonomou, E., and **Pintzas A.*** (2016). BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. *Oncotarget*. 7, 9188-9221.

Perimenis, P., Galaris, A., Voulgari, A., Prassa, M. and **Pintzas, A.*** (2016). IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. *BMC Cancer* 16, 624.

Oikonomou, E., Koustas, E., Goulielmaki, M. and **Pintzas, A.*** (2014). BRAF vs RAS Oncogenes: Are Mutations of the Same Pathway

Equal? Differential Signalling and Therapeutic Implications. *Oncotarget* 5, 11752-11777.
 Kosmidou, V., Oikonomou, E., Vlassi, M., Avlonitis, S., Katseli, A., Tsipras, I., Mourtzoukou, D., Kontogeorgos, G., Zografos, G. and **Pintzas, A.*** (2014). Tumor heterogeneity revealed by *KRAS*, *BRAF* and *PIK3CA* pyrosequencing: *KRAS* and *PIK3CA* intratumor mutation profile differences and their therapeutic implications. *Human Mutation* 35, 329-340.

Joyce, T., Oikonomou, E., Kosmidou, V., Makrodouli, E., Bantounas, I., Avlonitis, S., Zografos, G., and **Pintzas A.*** (2012). A molecular signature for oncogenic *BRAF* in human colon cancer cells is revealed by microarray analysis. *Current Cancer Drug Targets* 12, 873-898.
Pintzas, A.*, Zhivotovsky, B., Workman, P., Clarke, P.A., Linardopoulos, S., Martinou, J-C., Lacal, J.C., Robine, S., Nasioulas, G. and Andera, L. (2012). Sensitisation of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. *Cancer Biology and Therapy* 13, 507 – 515.

SELECTED COMPETITIVE FUNDING

TOTAL budget from competitive grants: > 5,000 kEuros

2025-2029: "PCM", Joint Action (JA) Personalised Cancer Medicine
 2024-2028: "JANE-2" Joint Action (JA) on Networks of Expertise on Cancer
 2022-2024: "JANE" Joint Action on Networks of Expertise on Cancer. European Health and Digital Executive Agency (HADEA)
 2018-2021: HNPM "Hellenic Network for Precision Medicine", a national network for precision oncology.
 2012-2015: "THERACAN", Exploiting molecular pathways of apoptotic cell death for the rational design of therapeutic strategies for colon cancer. National Strategic Reference Framework, Action "Co-operation II".
 2010-2015: "POM", *PIK3CA* Oncogenic Mutations in Breast and Colon Cancers: Development of Targeted Anticancer Drugs and Diagnostics. National Strategic Reference Framework, Action "Co-operation".
 2009-2012: "EpiDiaCan", Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer. 7FP EU- Cooperation –Theme "Health".
 2012-2014: "CancerStem-Less", Establishment and characterization of cancer stem cells from colorectal tumours, towards their sensitisation to modern therapeutic pharmacological strategies. National Strategic Reference Framework, Action "Supporting Postdoctoral Researchers"
 2006-2010: "Oncodeath" Resistant determinants and sensitisation of solid tumor cells to death receptor related therapies: combination of TRAIL with other therapeutic molecules. EU-Combating Cancer Programme.
 2006-2009: Functional oncogenomics: a powerful tool towards diagnosis and treatment of human colorectal cancer. Greek Research Network PENED.
 2004-2006: "Molecular mechanisms of tumour invasion and metastasis", Research cooperation programme between Greece and USA
 2003-2006: "In vivo and in silico analysis of gene expression induced by Ras oncogene in cancer", Greek Research Network PENED.
 1996-2000: "Cell signalling in development and disease", EU-TMR Research Network. Participation of 9 labs from 7 EU countries.

ADDITIONAL INFORMATION

2011-2025: Teaching in the frame of MSc in "Molecular & Applied Physiology", organised by the Medical School, NKUA. 2016-2026: Teaching in the frame of Master Courses co-organised by ICB/NHRF with the University of Thessaly ("Bioentrepreneurship") and with the University of Crete ("Oncology: from Oncogenesis to Therapy")

Participation in Scientific organisations

- **ACCC (Athens Comprehensive Cancer Center) member of the Council**
- EMBO (European Molecular Biology Organisation) Fellows Network
- EACR (European Association for Cancer Research)
- EORTC (European Organisation for Research and Treatment of Cancer - PAMM group)
- Marie Curie Fellowship Association

**Scientific and financial management for 3 large European and 3 Greek research funded programmes of total 30 collaborating organizations and of total budget 5,8 million Euros
Service/Consulting**

Member of Advisory Board of EU Network on Cancer Genomics
 Former Member of the National Assembly of Research and Technology (2003-2004)
 National Expert of 7 FP ERC IDEAS Programme (2006-2009)